{"url_path":"/sec/trda/8-k/2026-05-19/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","accession_number":"0001104659-26-063325","cik":"0001689375","ticker":"TRDA","issuer_name":"Entrada Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","primary_entity_key":"0001689375","primary_entity_name":"Entrada Therapeutics, Inc."},"word_count":309,"has_tables":true,"body_markdown":"false\n0001689375\n\n0001689375\n\n2026-05-18\n2026-05-18\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n \n\n**UNITED STATES**\n\n****\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nMay 18, 2026**\n\n \n\n \n\n**ENTRADA\nTHERAPEUTICS, INC.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n** **\n\n**Delaware**\n**001-40969**\n**81-3983399**\n\n**(State or other jurisdiction**\n**(Commission**\n**(I.R.S. Employer**\n\n**of incorporation)**\n**File Number)**\n**Identification No.)**\n\n \n\n**One Design Center Place**\n\n** ****Suite 17-500**\n\n \n \n\n**Boston, MA**\n \n**02210**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\n**Registrant’s telephone number, including area\ncode:** **(857****) 520-9158**\n\n \n\n**Not Applicable**\n\n**(Former name or former address, if changed since\nlast report)**\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n  \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n  \n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n  \n\n¨Pre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n \n**Trading\nSymbol(s)**\n \n**Name of each exchange\non which registered**\n\n**Common\nStock, $0.0001 par value per share**\n \n**TRDA**\n \n**The Nasdaq Global Market**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}